A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
The purpose of this study is to evaluate whether fostamatinib is safe and effective in the
 treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
Inclusion Criteria:

 Subject must have had a diagnosis of primary or secondary warm antibody AIHA.

 - Must have failed at least 1 prior treatment regimen for AIHA.

 Exclusion Criteria:

 -  Subject with cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or
 paroxysmal cold hemoglobinuria.

 -  Subject with a platelet count of < 30,000/μL.

 -  Subject has AIHA secondary to autoimmune disease, including systemic lupus
 erythematosis (SLE), or lymphoid malignancy and the underlying disease is not stable
 or is not well-controlled on current therapy.

 -  Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood
 pressure ≥ 130 mmHg, or diastolic blood pressure ≥ 80 mmHg.